Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma

Cisplatin-based chemotherapy is the standard of care for patients with muscle invasive urothelial carcinoma. Pathologic downstaging to pT0/pTis after neoadjuvant cisplatin-based chemotherapy is associated with improved survival, although molecular determinants of cisplatin response are incompletely...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Discov
Main Authors: Van Allen, Eliezer M., Mouw, Kent W., Kim, Philip, Iyer, Gopa, Wagle, Nikhil, Al-Ahmadie, Hikmat, Zhu, Cong, Ostrovnaya, Irina, Kryukov, Gregory V., O’Connor, Kevin W, Sfakianos, John, Garcia-Grossman, Ilana, Kim, Jaegil, Guancial, Elizabeth A., Bambury, Richard, Bahl, Samira, Gupta, Namrata, Farlow, Deborah, Qu, Angela, Signoretti, Sabina, Barletta, Justine A., Reuter, Victor, Boehm, Jesse, Lawrence, Michael, Getz, Gad, Kantoff, Philip, Bochner, Bernard H., Choueiri, Toni K., Bajorin, Dean F., Solit, David B., Gabriel, Stacey, D’Andrea, Alan, Garraway, Levi A., Rosenberg, Jonathan E.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2014
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4238969/
https://ncbi.nlm.nih.gov/pubmed/25096233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-0623
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים